FIELD: medicine.SUBSTANCE: group deals with methods for stabilisation of active pharmaceutical ingredient in concentrated solution for oral introduction, which includes 42-52 wt % of water, 47-57 wt % of polyethyleneglycol, which has average molecular weight 3015-3685 Dalton； 0.05-0.36% of sodium benzoate and pharmaceutically acceptable acid. Described methods include stages, at which (a) quantity of pharmaceutically acceptable acid is corrected for pH value to be in the range 3.0-5.0 at temperature 25C； and (b) concentrated solution is packed into hermetic container, which has rate of oxygen penetration into dry container not higher than 0.1 cm/container/day from air at pressure of one atmosphere (0.1 MPa) and temperature 25°C, measured in accordance with ASTM F-1307-02 standard； or (b) concentrated solution is packed into hermetic bottle, made of polymer resin, which has oxygen permeability higher than 100 cm-mil/100 inchatm-day (39.4 cm·mm/m-24 h-atm), being measured in form of film, or (B) concentrated solution is packed into hermetic container, made of polymer, which has oxygen permeability lower than 100 cm-mil/100 inchatm-day (39.4 cm·mm/m-24 h-atm),being measured in form of film.EFFECT: obtaining concentrated polyethyleneglycol solution, which has good long storage stability, with minimised accumulation of degradation products.41 cl, 8 ex, 8 tblГруппа изобретений относится к фармацевтической области и касается способов стабилизации активного фармацевтического ингредиента в концентрированном растворе для орального введения, который включает 42-52 мас.% воды, 47-57 мас.% полиэтиленгликоля, имеющего среднюю молекулярную массу 3015-3685 Дальтон； 0,05-0,36% бензоата натрия и фармацевтически приемлемую кислоту. Описанные способы включают стадии, в которых (а) корректируют количество фармацевтически приемлемой кислоты, чтобы значение рН при температуре при 25С было в диапазоне 3,0-5,0； и (b) упаковывают концентрированный раствор в герметичный контейнер, который име
